The essentials
Acting AG reclassifies medical marijuana to Schedule III via expedited process following presidential directive.
Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana from Schedule I to Schedule III, marking a significant shift in federal drug policy classification.
The reclassification follows President Trump's December order to accelerate the marijuana reclassification process. Rather than proceeding through conventional channels, Blanche's order employs an international treaty provision to sidestep the traditional DEA review process, a procedural approach that circumvents standard regulatory procedures.
The action precedes a scheduled federal hearing on June 29 to consider broader marijuana reclassification proposals. This expedited timeline contrasts with the previous administration's approach—the Biden administration proposed marijuana reclassification in 2024 and received 43,000 public comments, following established regulatory timelines.
The shift represents a fundamental change in how Schedule I substances—defined as having no accepted medical use—are federally categorized for medical purposes.
Other ways to read this story.
Alternative framings generated by SigNews. These are not independent sources or attributed quotations.
Executive Action Accelerates Reclassification Without Standard Review
The reclassification represents an expedited executive approach that bypasses traditional DEA procedures. Blanche's order uses an international treaty provision to achieve immediate reclassification of state-licensed medical marijuana to Schedule III. This contrasts with the previous administration's multi-month public comment period, which generated 43,000 responses. The June 29 hearing will address broader reclassification questions.
Reclassification Accelerated Following Presidential Directive in December
President Trump ordered acceleration of the reclassification process in December, prompting Acting AG Blanche's swift action on medical marijuana. The Biden administration's 2024 proposal represented a traditional regulatory path with extensive public input. The current approach compresses this timeline significantly, with a federal hearing already scheduled for June 29 to consider additional reclassification scope.